Skip to main content

Radiation Oncology

Submissions from 2020 2020

Median 50 Gy in 5 Consecutive Fractions Delivered with Stereotactic Magnetic Resonance Image-guided Radiation Therapy for Inoperable Pancreas Cancer, Michael Chuong, Rupesh Kotecha, Matthew Hall, Jessika Contreras, Kathryn Mittauer, Diane Alvarez, Tino Romaguera, Gustavo Luciani, Vivek Mishra, and Alonso Gutierrez

Early posttherapy clearance of human papillomavirus and treatment response in cervical carcinoma, Jessika Contreras

Long-term outcomes of intensity-modulated radiation therapy (IMRT) and high dose rate brachytherapy as adjuvant therapy after radical hysterectomy for cervical cancer, Jessika Contreras

Preservation of swallowing in resected oral cavity squamous cell carcinoma: examining radiation volume effects (PRESERVE): study protocol for a randomized phase II trial, Jessika Contreras and Noah Kalman

Radiotherapy and Late Effects, Matthew Hall

Residual setup errors in cranial stereotactic radiosurgery without six degree of freedom robotic couch: Frameless versus rigid immobilization systems, Matthew Hall

Pediatric bithalamic gliomas have a distinct epigenetic signature and frequent EGFR exon 20 insertions resulting in potential sensitivity to targeted kinase inhibition, Matthew Hall and Minesh Mehta

Simulation of an HDR "Boost" with Stereotactic Proton versus Photon Therapy in Prostate Cancer: A Dosimetric Feasibility Study, Adeel Kaiser

The Association Between Laboratory Pretreatment Immune Parameters and Radiographic Lung Changes in Early Stage Lung Cancer Patients Undergoing Stereotactic Body Radiation Therapy, Noah Kalman

Analyzing the role of adjuvant or salvage radiotherapy for spinal myxopapillary ependymomas, Rupesh Kotecha

Brain metastases from non-small cell lung cancer with EGFR or ALK mutations: A systematic review and meta-analysis of multidisciplinary approaches, Rupesh Kotecha

CTIM-22. PHASE 1 TRIAL OF OSIMERTINIB WITH STEREOTACTIC RADIOSURGERY (SRS) IN PATIENTS WITH BRAIN METASTASES FROM EGFR POSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC), Rupesh Kotecha

Current approaches to the management of brain metastases, Rupesh Kotecha

Management of recurrent or progressive spinal metastases: reirradiation techniques and surgical principles, Rupesh Kotecha

Multi-institutional validation of brain metastasis velocity, a recently defined predictor of outcomes following stereotactic radiosurgery, Rupesh Kotecha

Response to letter regarding "Stereotactic radiosurgery for nonfunctioning pituitary adenomas: meta-analysis and International Society of Stereotactic Radiosurgery (ISRS) practice opinion", Rupesh Kotecha

Impact of Radiotherapy Dosimetric Parameters on Neurocognitive Function in Brain Tumor Patients, Rupesh Kotecha and Matthew Hall

Extreme Hypofractionation for Newly Diagnosed Glioblastoma: Rationale, Dose, Techniques, and Outcomes, Rupesh Kotecha and Minesh Mehta

Stereotactic Radiosurgery for Non-Functioning Pituitary Adenomas: Meta-Analysis and International Society of Stereotactic Radiosurgery (ISRS) Practice Opinion, Rupesh Kotecha and Muni Rubens

Radiation therapy alone versus radiation therapy plus radiofrequency ablation/vertebral augmentation for spine metastasis: study protocol for a randomized controlled trial, Rupesh Kotecha, Brian Schiro, Justin Sporrer, Muni Rubens, Haley Appel, Kathleen Calienes, Belinda Boulanger, Marietsy Pujol, Deborah Suarez, Ashley Pena, Alex Kudryashev, and Minesh Mehta

Pulsed-reduced dose rate (PRDR) radiotherapy for recurrent primary central nervous system malignancies: dosimetric and clinical results, Tugce Kutuk, Alexander Mohler, Nicole McAllister, Matthew Hall, Martin Tom, Haley Appel, Ranjini Tolakanahalli, Alonso Gutierrez, Yazmin Odia, Manmeet Ahluwalia, Minesh Mehta, and Rupesh Kotecha

30. RADIOSURGERY FOLLOWED BY TUMOR TREATING FIELDS FOR BRAIN METASTASES (1–10) FROM NSCLC IN THE PHASE 3 METIS TRIAL, Minesh Mehta

Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma, Minesh Mehta

Effectiveness of Radiofrequency Ablation in the Treatment of Painful Osseous Metastases: A Correlation Meta-Analysis with Machine Learning Cluster Identification, Minesh Mehta

Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions, Minesh Mehta

High-risk meningioma: Initial outcomes from NRG Oncology/RTOG 0539, Minesh Mehta

Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001, Minesh Mehta

Investigating Low-Dose Thoracic Radiation as a Treatment for COVID-19 Patients to Prevent Respiratory Failure, Minesh Mehta

Low-Dose Radiation Therapy (LDRT) for COVID-19: Benefits or Risks?, Minesh Mehta

NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma, Minesh Mehta

Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients, Minesh Mehta

Phase 2 Study of a Temozolomide-Based Chemoradiation Therapy Regimen for High-Risk, Low-Grade Gliomas: Long-Term Results of Radiation Therapy Oncology Group 0424, Minesh Mehta

Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02, Minesh Mehta

Phase II Study of a Temozolomide-Based Chemo-radiotherapy Regimen for High Risk Low-Grade Gliomas: Long-term Results of Radiation Therapy Oncology Group (RTOG) 0424, Minesh Mehta

Putative Abscopal Effect in Three Patients Treated by Combined Radiotherapy and Modulated Electrohyperthermia, Minesh Mehta

Radiotherapy Innovations to Optimize Brain Metastases Control, Minesh Mehta

CTIM-15. PRELIMINARY RESULTS OF A PHASE II STUDY OF NIVOLUMAB WITH HYPOFRACTIONATED RE-RADIATION AND BEVACIZUMAB FOR RECURRENT MGMT METHYLATED GLIOBLASTOMA, Minesh Mehta, Rupesh Kotecha, and Yazmin Odia

CTNI-17. CLINICAL EFFICACY AND PREDICTIVE BIOMARKERS OF ONC201 IN H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA, Minesh Mehta, Yazmin Odia, Matthew Hall, and Doured Daghistani

HGG-18. CLINICAL EFFICACY OF ONC201 IN THALAMIC H3 K27M-MUTANT GLIOMA, Minesh Mehta, Yazmin Odia, Matthew Hall, and Doured Daghistani

A Novel Pre-plan Technique for On-table Adaptation of Pancreatic Stereotactic MR-guided Online Adaptive Radiotherapy, Kathryn Mittauer, Michael Chuong, Jessika Contreras, Diane Alvarez, Tino Romaguera, Rupesh Kotecha, Matthew Hall, Minesh Mehta, and Alonso Gutierrez

DIPG-52. PHASE I CLINICAL TRIAL OF ONC201 IN PEDIATRIC H3 K27M-MUTANT GLIOMA OR NEWLY DIAGNOSED DIPG, Yazmin Odia, Matthew Hall, and Doured Daghistani

ONC201 in previously irradiated pediatric H3 K27M-mutant glioma or newly diagnosed DIPG, Yazmin Odia, Matthew Hall, and Doured Daghistani

Biological activity of weekly ONC201 in adult recurrent glioblastoma patients, Yazmin Odia and Minesh Mehta

Clinical experience of ONC201 in patients with recurrent H3 K27M-mutant spinal cord glioma, Yazmin Odia and Minesh Mehta

Early imaging marker of progressing glioblastoma: a window of opportunity, Yazmin Odia and Minesh Mehta

Single-agent ONC201 in recurrent H3 K27M-mutant diffuse midline glioma, Yazmin Odia and Minesh Mehta

RADT-31. PATTERNS OF CARE IN THE USE OF ADJUVANT RADIOTHERAPY AND CHEMOTHERAPY IN LOW GRADE GLIOMA PATIENTS IN THE UNITED STATES FROM 2010-2016, Warren Rehrer, Yazmin Odia, Muni Rubens, Noah Kalman, Michael Chuong, Rupesh Kotecha, Minesh Mehta, and Matthew Hall

The Use of Adjuvant Radiotherapy and Chemotherapy in Low Grade Glioma Patients in the United States from 2010-2016, Warren Rehrer, Muni Rubens, Katherine Von Werne, Yazmin Odia, Michael Chuong, Rupesh Kotecha, Minesh Mehta, and Matthew Hall

Principles of Radiation Therapy in Breast Cancer, Maria-Amelia Rodrigues

Recent Health Care Expenditure Trends Among Adult Cancer Survivors in United States, 2009-2016, Muni Rubens, Anshul Saxena, Sankalp Das, Chintan Bhatt, Emir Veledar, Peter McGranaghan, Ana Viamonte Ros, Yuliya Linhares, Yazmin Odia, Michael Chuong, Rupesh Kotecha, and Minesh Mehta

Survival Impact Of Postoperative Radiotherapy Timing In Pediatric And Young Adult Ependymoma, Sunny Shah, Kevin Gates, Chase Mallory, Muni Rubens, Haley Appel, Noah Kalman, Rupesh Kotecha, Minesh Mehta, and Matthew Hall

Safety of Proton Therapy for Patients With Primary Central Nervous System Germinoma and Non-Germinomatous Germ Cell Tumors: Report from a Multi-Institutional Database Analysis, Katherine Von Werne, Melanie Naranjo, Haley Appel, Warren Rehrer, Muni Rubens, Michael Chuong, Minesh Mehta, Rupesh Kotecha, and Matthew Hall

Submissions from 2019 2019

Prediction of Anal Cancer Recurrence After Chemoradiotherapy Using Quantitative Image Features Extracted From Serial (18)F-FDG PET/CT, Michael Chuong

Consensus Report From the Miami Liver Proton Therapy Conference, Michael Chuong and Alonso Gutierrez

Estimating survival in patients with gastrointestinal cancers and brain metastases: An update of the graded prognostic assessment for gastrointestinal cancers (GI-GPA), Michael Chuong and Minesh Mehta

Survival and prognostic factors in patients with gastrointestinal cancers and brain metastases: have we made progress?, Michael Chuong and Minesh Mehta

EBV-positive primary CNS lymphoma restricted to the conus medullaris in an immunocompetent host, Matthew Hall, Lyle Feinstein, Sergio Gonzalez-Arias, and Yazmin Odia

First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report, Matthew Hall, Yazmin Odia, Doured Daghistani, and Minesh Mehta

Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201, Matthew Hall, Yazmin Odia, and Minesh Mehta

CMET-06. AN ANALYSIS OF RESPONSE ENDPOINTS FOR BRAIN METASTASIS PATIENTS TREATED WITH STEREOTACTIC RADIOSURGERY AND PD(L)-1 INHIBITORS, Rupesh Kotecha

Stereotactic radiosurgery with concurrent HER2-directed therapy is associated with improved objective response for breast cancer brain metastasis, Rupesh Kotecha

Stereotactic radiosurgery with concurrent lapatinib is associated with improved local control for HER2-positive breast cancer brain metastases, Rupesh Kotecha

Ten-year outcomes of moderately hypofractionated (70 Gy in 28 fractions) intensity modulated radiotherapy for localized prostate cancer, Rupesh Kotecha

The Impact of Sequencing PD-1/PD-L1 Inhibitors and Stereotactic Radiosurgery for Patients with Brain Metastasis, Rupesh Kotecha

The Complexity of Managing Large Brain Metastasis, Rupesh Kotecha and Minesh Mehta

Updates in the management of intradural spinal cord tumors: a radiation oncology focus, Rupesh Kotecha and Minesh Mehta

Barriers to Accrual and Enrollment in Brain Tumor Trials, Minesh Mehta

Comparison of Epidemiology and Outcomes in Neuro-Oncology Between the East and the West: Challenges and Opportunities, Minesh Mehta

Defining an Intermediate-risk Group for Low-grade Glioma: A National Cancer Database Analysis, Minesh Mehta

Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma, Minesh Mehta

Influence of Residual Disease Following Surgical Resection in Newly Diagnosed Glioblastoma on Clinical, Neurocognitive, and Patient Reported Outcomes, Minesh Mehta

Letter: When Less is More: Dexamethasone Dosing for Brain Tumors, Minesh Mehta

Low-Grade Glioma Radiotherapy Treatment and Trials, Minesh Mehta

Management of patients with brain metastases from non-small cell lung cancer and adverse prognostic features: multi-national radiation treatment recommendations are heterogeneous, Minesh Mehta

MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges, Minesh Mehta

NRG brain tumor specialists consensus guidelines for glioblastoma contouring, Minesh Mehta

Preoperative Vs Postoperative Radiosurgery For Resected Brain Metastases: A Review, Minesh Mehta

Pretreatment Volume of MRI-Determined White Matter Injury Predicts Neurocognitive Decline After Hippocampal Avoidant Whole-Brain Radiation Therapy for Brain Metastases: Secondary Analysis of NRG Oncology Radiation Therapy Oncology Group 0933, Minesh Mehta

The association between BMI and BSA–temozolomide-induced myelosuppression toxicities: a correlative analysis of NRG oncology RTOG 0525, Minesh Mehta

Lack of Efficacy of the Neutropenic Diet in Decreasing Infections among Cancer Patients: A Systematic Review, Muni Rubens, Anshul Saxena, Peter McGranaghan, Emir Veledar, Ana Viamonte Ros, and Rupesh Kotecha

Submissions from 2018 2018

Combining immunotherapy with radiation therapy in thoracic oncology, Michael Chuong

Correlation of radiation dose and activity with clinical outcomes in metastatic colorectal cancer after selective internal radiation therapy using yttrium-90 resin microspheres, Michael Chuong

Mid/Distal Esophageal Cancer and Gastroesophageal Junction Cancer (Siewert Type I and II), Michael Chuong

Minimal toxicity after proton beam therapy for prostate and pelvic nodal irradiation: results from the proton collaborative group REG001-09 trial, Michael Chuong

The Case for Proton Beam Therapy, Michael Chuong

Improving the therapeutic index for nonoperable esophageal cancer patients with modern radiation technologies, Michael Chuong and Matthew Hall

Pencil beam scanning versus passively scattered proton therapy for unresectable pancreatic cancer, Michael Chuong, Man Yam, and Minesh Mehta

Proton beam therapy for gastrointestinal cancers: past, present, and future, Matthew Hall and Michael Chuong

Early Objective Response as a Prognosticator for Final Objective Response and Survival following SRS for Brain Metastases Treated with Concurrent Systemic Therapy, Rupesh Kotecha

Effect of Switching Systemic Treatment After Stereotactic Radiosurgery for Oligoprogressive, Metastatic Renal Cell Carcinoma, Rupesh Kotecha

(OA13) Stereotactic Radiosurgery and Concurrent Targeted Therapy: Improving the Response Rate for Breast Cancer Brain Metastasis, Rupesh Kotecha

Proton therapy patterns of care among pediatric and adult patients with CNS tumors, Rupesh Kotecha

Stereotactic Radiosurgery (SRS) with Immune Checkpoint Inhibitor Therapy (ICI) for Patients with Brain Metastasis (BM): The Impact of Timing and Sequencing, Rupesh Kotecha

Ten-Year Outcomes and Toxicity with Moderately Hypofractionated (70 Gy in 28 fractions) Intensity-Modulated Radiation Therapy for Localized Prostate Cancer, Rupesh Kotecha

Recent advances in managing brain metastasis, Rupesh Kotecha and Minesh Mehta

A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: Results of NRG Oncology RTOG 0913, Minesh Mehta

Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial, Minesh Mehta

Brain Metastases in Lung Cancer With Targetable Mutations-Reply, Minesh Mehta

Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group, Minesh Mehta

Consolidative Whole-Brain Radiation Therapy Versus Autologous Stem Cell Transplant for Primary Central Nervous System Lymphoma: A Large Dose of Perspective and Perhaps a Lower Dose of Radiation Are in Order, Minesh Mehta